Clinical Trial Update: Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for Descartes-08, an mRNA CAR T-cell therapy, evaluating its use in myasthenia gravis and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Descartes-08

Snippet

Sponsor: Cartesian Therapeutics | Conditions: Myasthaenia Gravis | Phase 3 | Status: RECRUITING